Progress in cancer genetics: Lessons from pancreatic cancer

Annals of Oncology

Volumn 10, Issue SUPPL. 4, 1999, Pages

  Goggins, Michael ^a   Kern, S E ^a   Offerhaus, J A ^b   Hruban, R H ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

ALK 5; BRCA2; DPC4; Mismatch repair; p16; Pancreas cancer; Tumor suppressor genes

Indexed keywords

PROTEIN P16; PROTEIN P53; TELOMERASE;

CANCER GENETICS; CANCER SCREENING; CHROMOSOME ABERRATION; CONFERENCE PAPER; DNA METHYLATION; HUMAN; ONCOGENE K RAS; PANCREAS CANCER; PEUTZ JEGHERS SYNDROME; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0032812487     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/10.suppl_4.S4     Document Type: Conference Paper

References (87)

1. Kern SE. Clonality: more than just a tumor-progression model. J Natl Cancer Inst 1993;85:1020-1.
2. Familial Cancer Syndromes: The role of caretakers and gatekeepers. In: The Genetic Basis of Human Cancer, pgs 241-2. Eds; Vogelstein B, and Kinzler KW. 1998 MacGraw Hill.
3. Kern SE. Progressive genetic abnormalities in human neoplasia. In: Molecular basis of Cancer. Eds; J Mendelsohn, M Israel, L Liotta, PM Howley.
4. Heldin, C. H., Miyazono, K., ten Dijke, P. TGF-b signaling from cell membrane to nucleus through SMAD proteins. Nature 1997;390:465-71.
5. Zawel L, Dai JL, Buckhaults P et al. Human Smad3 and Smad4 are sequence specific transcription activators. Mol Cell 1998;1:611-7.
6. de Winter JP, Roelen BA, ten Dijke P et al. DPC4 (SMAD4) mediates transforming growth factor-beta1 (TGF-beta1) induced growth inhibition and transcriptional response in breast tumour cells. Oncogene 1997;14:1891-9.
7. Reiss M. Transforming growth factor-beta and cancer: a love-hate relationship? Oncology Research.9:447-57, 1997
8. Hahn, S. A., Schutte, M., Hoque, A. T. M. S. et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996;271:350-3,.
9. Schutte, M., Hruban, R. H., Hedrick, L. et al. DPC4 gene in various tumor types. Cancer Res. 56, 2527-30 1996.
10. Goggins M, Shekher M, Turnaniglu K et al. Genetic alterations of the TGFb receptor genes in pancreatic and biliary adenocarcinomas. Cancer Research 1998: in press.
11. Markowitz, S., Wang, J., Myeroff, L. et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science. 268: 1336-38 1995.
12. Garrigue-Antar, L., Munoz-Antonia, T., Antonia, S.J. et al. Missense mutations of the transforming growth factor b type II receptor in human head and neck squamous carcinoma cells. Cancer Res 1995;55:3982-7.
13. Riggins GJ, Thiagalingam S, Rozenblum E et al. Mad-related genes in the human. Nat Genet 1996;13:347-9
14. Eppert, K., Scherer, S.W., Ozcelik, H. et al. MADR2 maps to 18q21 and encodes a TGF-b-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 86;543-52: 1996
15. Hahn SA, Bartsch D, Schroers A. et al. Mutations of the DPC4/Smad4 gene in biliary tract carcinoma. Cancer Res 1998;58:1124-6.
16. Thiagalingam S, Lengauer C, Leach FS et al. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet 1996;13:343-6.
17. Baldwin RL, Friess H, Yokoyama M et al. Attenuated ALK5 receptor expression in human pancreatic cancer: correlation with resistance to growth inhibition. Int J Cancer 1996;67:283-8..
18. Lukas J, Parry D, Aagaard L et al. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 1995;375:503-6
19. Scherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
20. Kamb A, Shattuck-Eidens D, Eeles R et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genetics 1994;8:23-6.
21. Goldstein AM, Fraser MC, Struewing JP et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 1995;333: 970-74.
22. Caldas C, Hahn SA, da Costa LT et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genetics 1994;8:27-31
23. Schutte M, Hruban RH, Geradts J et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997;57:3126-30.
24. Hollstein M, Sidransky D, Vogelstein B et al. p53 mutations in human cancers. Science 1991;253(5015):49-53.
25. Rozenblum E, Schutte M, Goggins M et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997;57:1731-4.
26. Redston MS, Caldas C, Seymour AB et al. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994;54:3025-33.
27. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
28. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998;92:725-34.
29. Pomerantz J, Schreiber-Agus N, Liegeois NJ et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998;92:713-23.
30. Kamijo T, Zindy F, Roussel MF et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997;91:649-59
31. Graeber TG, Peterson JF, Tsai M et al. Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol 1994;14:6264-77.
32. An WG, Kanekal M, Simon MC et al. Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature 1998;392:405-8.
33. Carmeliet P, Dor Y, Herbert JM et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998;394:485-90.
34. Graeber TG, Osmanian C, Jacks T et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996;379:88-91.
35. Polyak, K Xia Y, Zweier JL et al. A model for p53-induced apoptosis Nature 1997;389: 300-5
36. Hermeking H, Lengauer C, Polyak K et al. 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1997;1:3-11
37. Bunz F, Dutriaux A, Lengauer C et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998: 1497-1501.
38. Waterman MJF, Stavridi ES, Waterman JLF et al. ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nat Genet 1998;19:175-8
39. Bouvet M, Ellis LE, Nishizaki M et al. Adenovirus-mediated Wild-Type p53 Gene Transfer Down-Regulates Vascular Endothelial Growth Factor Expression and Inhibits Angiogenesis in Human Colon Cancer. Cancer Res 1998;58:2288-92
40. ING1 cooperates with p53 in cell growth control. Nature 1998;391: 295.
41. Polyak K, Li Y, Zhu H et al. Somatic mutations of the mitochondrial genome in human colorectal tumors. Nature Genet 1998;20:291-3.
42. Sharan SK, Morimatsu M, Albrecht U et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 1997;386:804-10.
43. Abbott DW, Freeman ML, Holt JT. Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. J Natl Can Inst 1998;90:978-85.
44. Struewing JP, Hartge P, Wacholder S et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8
45. Goggins M, Schutte M, Lu J et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996;56:5360-4
46. Ozcelik H, Schmocker B, Di Nicola N et al. Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nat Genet 1997;16:17-8.
47. Tonin P, Weber B. Offit Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med. 1996;2:1179-83
48. Giardiello FM, Welsh SB, Hamilton SR et al. Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med 1987;316:1511-4
49. Su GH, Hruban RH, Bansal RK et al. Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Submitted.
50. Lowenfels AB, Maisonneuve P, DiMagno EP et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Instit 1997;89:442-6.
51. Whitcomb DC, Gorry MC, Preston RA et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene Nature Genetics 1996;14:141-5
52. Su, G. H., Hilgers, W., Shekher, M. et al. Alternations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. Cancer Res. 58: 2339-42 1998.
53. Goggins M, Hilgers W, Hruban RH et al. Normal beta-catenin gene in pancreatic cancer. NOGO 1997;1:4.
54. Okami K, Wu L, Riggins G et al. Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors. Cancer Res 1998;58:509-11
55. Almoguerra C, Shibata D, Forrester K et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;53:549-54
56. Hruban RH, van Mansfeld ADM, Offerhaus GJA et al. K-ras oncogene activation in adenocarcinomas of the human pancreas: a study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993;143:545-54
57. Day JD, Digiuseppe JA, Yeo C et al. Immunohistochemical evaluation of HER2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. Human Pathology 1996;27:119-24
58. Goggins, M., Offerhaus, G. J. A., Hilgers, W. et al. Adenocarcinomas of the pancreas with DNA replication errors (RER+) are associated with a characteristic histopathology: poor differentiation, a syncytial growth pattern, and pushing borders suggest RER. Am J Pathol 1998;152:1501-7.
59. Tada M, Omata M, Ohto M. Ras gene mutations in intraductal papillary neoplasms of the pancreas. Analysis in five cases. Cancer 1991;67:634-7
60. Caldas C, Hahn SA, Hruban RH et al. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 1994;54:3568-73
61. Yamada T, Nakamori S, Ohzato H et al. Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features. Clinical Cancer Research 1998;4:1527-32.
62. Mulcahy HE, Lyautey J, Lederrey C et al. A prospective study of K-ras mutations in the plasma of pancreatic cancer patients. Clinical Cancer Research 1998;4:271-5.
63. Wilentz RE, Chung CH, Sturm PD et al. K-ras mutations in the duodenal fluid of patients with pancreatic carcinoma. Cancer 1998;82:96-103
64. Hua VY, Wang WK, Duesberg PH. Dominant transformation by mutated human ras genes in vitro requires more than 100 times higher expression than is observed in cancers. Proceedings of the National Academy of Sciences of the United States of America 1997;94:9614-9
65. Liu M, Bryant MS, Chen J et al. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res 1998;58:4947-56
66. Vasen HFA, Mecklin JP, Meera Khan P et al. The international collaborative group on hereditary nonpolyposis colorectal cancer (ICG-HNPCC). Dis Colon Rectum 1991;34:424-5
67. Lynch HT, Smyrk TC, Lynch JF. Overview of natural history, pathology, molecular genetics and management of HNPCC (Lynch Syndrome). Int J Cancer 1996;69:38-43.
68. Boland CR. Hereditary non-polyposis colorectal cancer. In: The genetic basis of human cancer, pgs. 333-346. Eds: Vogelstein B, and Kinzler K. MacGraw Hill, 1998.
69. Jass JR, Smyrk TC, Stewart SM et al. Pathology of hereditary nonpolyposis colon cancer. Anticancer Res 1994;14:1631-34.
70. Kim H, Jen J, Vogelstein B et al. Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol 1994;145:148-156.
71. Kouri M, Laasonen A, Mecklin JP et al. Diploid predominance in hereditary nonpolyposis colorectal carcinoma evaluated by flow cytometry. Cancer 1989;65:1825-9.
72. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature 1997;386:623-7.
73. Cahill DP, Lengauer C, Yu J et al. Mutations of mitotic checkpoint genes in human cancers Nature 1998;392:300-3
74. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983;301:89-92.
75. Goelz SE, Vogelstein B, Hamilton SR et al. Hypomethylation of DNA from benign and malignant human colon neoplasms. Science 1985;228:187-90
76. Lengauer C, Kinzler KW, Vogelstein B. DNA methylation and genetic instability in colorectal cancer cells. Proc Natl Acad Sci U S A 1997;94:2545-50.
77. R Z Chen, U Pettersson, C Beard et al. DNA hypomethylation leads to elevated mutation rates Nature 1998;395:089
78. Baylin SB, Herman JG, Graff JR et al. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998;72:141-96
79. Feinberg AP. Genomic imprinting and cancer. In: The genetic basis of human cancer, pgs 95-108. Eds: Vogelstein B, and Kinzler K. MacGraw Hill 1998.
80. Cui H, Horon IL, Ohlsson R et al. Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nature Med 1998;4:1276-80.
81. Hahn SA, Seymour AB, Hoque ATMS et al. Allelotype of pancreatic adenocarcinoma using a xenograft model. Cancer Res 1995;55:4670-5.
82. Griffin CA, Hruban RH, Morsberger LA et al. Consistent chromosome abnormalities in adenocarcinoma of the pancreas. Cancer Res 1995;55:2394-9
83. Miwa W, Yasuda J, Murakami Y et al. Isolation of DNA sequences amplified at chromosome 19q13.1-q13.2 including the AKT2 locus in human pancreatic cancer. Biochem Biophys Res Commun 1996;225:968-74.
84. Cheng JQ, Ruggeri B, Klein WM et al. Amplification of AKT2 in human pancreatic cancer cells and inhibition of AKT2 expression and tumorigenecity by antisense RNA. Proc Natl Acad Sci USA 1996;93:3636-41.
85. Wallrapp C, Muller-Pillasch F, Solinas-Toldo S et al. Characterization of a high copy number amplification at 6q24 in pancreatic cancer identifies c-myb as a candidate oncogene. Cancer Res 1997;57:3135-9.
86. Kim NW, Piatyszek MA, Prowse KR et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-5
87. Hiyama E, Kodama T, Shinbara K et al. Telomerase activity is detected in pancreatic cancer but not in benign tumors. Cancer Res 1997;57:326-31.